1. Clinical & Scientific Overview
Vitamin D3 (Cholecalciferol — including 60,000 IU High-Strength Preparations) (TIP-MED-000186, Reference Code [10.2]) is classified under
Vitamins, Minerals & Nutritional Supplements (Ch 10) as a Fat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Renally by 1-Alpha-Hydroxylase to Active 1,25(OH)2D [Calcitriol]).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.2], p. 127): Uprise-D3 60K (Alkem), Calcirol 60K (Cadila), Arachitol 60K / Nano (Abbott), D-Rise 60K (USV), Lumia 60K (Sun Pharma), Tayo 60K; Daily Maintenance Drops/Tablets: 400 IU, 1000 IU, 2000 IU — Strengths & Dosage Forms: High-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solution Shots (5 mL): 60,000 IU (1.5 mg Cholecalciferol); Daily Tablets: 1000 IU, 2000 IU; Parenteral IM Depot Injection (Arachitol): 3,00,000 IU, 6,00,000 IU (Use oral over mega-IM doses whenever possible!)
High-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solution Shots (5 mL): 60,000 IU (1.5 mg Cholecalciferol); Daily Tablets: 1000 IU, 2000 IU; Parenteral IM Depot Injection (Arachitol): 3,00,000 IU, 6,00,000 IU (Use oral over mega-IM doses whenever possible!)
3. Mechanism of Action & Pharmacodynamics
Fat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Renally by 1-Alpha-Hydroxylase to Active 1,25(OH)2D [Calcitriol]) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutritional Supplements (Ch 10): clinical efficacy is mediated via Fat-Soluble Secosteroid Prohormone (Converted Hepatically to 25(OH)D [Calcifediol] and Renally by 1-Alpha-Hydroxylase to Active 1,25(OH)2D [Calcitriol]) for Treatment and prevention of Vitamin D deficiency (<20 ng/mL) and insufficiency (20–30 ng/mL); nutritional osteomalacia and rickets; adjunct to calcium and bisphosphonates in osteoporosis; prevention of corticosteroid-induced and anticonvulsant-induced bone loss; reduction of proximal myopathy and falls in the elderly..
4. Therapeutic Indications & Evidence-Supported Uses
- Treatment and prevention of Vitamin D deficiency (<20 ng/mL) and insufficiency (20–30 ng/mL)
- nutritional osteomalacia and rickets
- adjunct to calcium and bisphosphonates in osteoporosis
- prevention of corticosteroid-induced and anticonvulsant-induced bone loss
- reduction of proximal myopathy and falls in the elderly
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference (Endocrine Society / Indian Consensus): • Loading Phase (Deficiency Correction): 60,000 IU orally ONCE A WEEK (e.g., every Sunday) for 6 to 8 weeks! • Maintenance Phase: 60,000 IU orally ONCE A MONTH (or 1000–2000 IU daily). CRITICAL WARNING: 60,000 IU is a WEEKLY/MONTHLY strength—NEVER take 60,000 IU daily! Follow physician prescription.
Administration & Meal Timing: MUST be taken WITH a fat-containing meal or a glass of warm full-cream milk! (Vitamin D3 is highly lipophilic/fat-soluble; taking a 60,000 IU capsule or sachet with a meal containing healthy fats [milk, curd, ghee, nuts, dal] increases intestinal lymphatic absorption by 32% to 50% compared to taking it with plain water on an empty stomach!). | Once weekly (on a fixed day, e.g., Sunday) immediately after breakfast, lunch, or dinner (or with bedtime milk).
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.
Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.
Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated in hypercalcaemia, hypervitaminosis D, malabsorption syndromes (unless water-miscible nano-micellar oral shots are used), and hypercalciuria/active calcium nephrolithiasis. Caution in sarcoidosis and granulomatous diseases (tuberculosis/lymphoma—macrophages convert 25(OH)D to active 1,25(OH)2D in an unregulated manner, causing hypercalcaemia!).
Key Clinical Precautions: Renal: Important CKD Distinction (Cholecalciferol vs. Calcitriol/Alfacalcidol): Native Vitamin D3 (Cholecalciferol) requires renal 1-alpha-hydroxylase activation in the proximal tubule. In CKD Stages 1–3, Cholecalciferol 60k corrects nutritional 25(OH)D deficiency. However, in advanced CKD Stage 4–5 and Dialysis (eGFR <30 mL/min) with secondary hyperparathyroidism, active vitamin D analogues—Calcitriol (Rocaltrol / Gemsitrol 0.25 mcg) or Alfacalcidol (Alpha D3 0.25 mcg)—are required, with strict monitoring of Serum Calcium and Phosphorus! Hepatic: Safe; water-miscible nano-shots absorb better in cholestasis.
8. Adverse Effects Profile
- Zero adverse effects within physiological replacement doses.
- Hypervitaminosis D and Severe Hypercalcaemia (Serum 25(OH)D >100–150 ng/mL, caused by accidental daily intake of 60,000 IU capsules or repeated unmonitored 6,00,000 IU IM injections!): presents with anorexia,intractable nausea, vomiting, constipation, polyuria, polydipsia, confusion/lethargy, nephrocalcinosis, renal calculi, and Acute Kidney Injury!
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Thiazide Diuretics (Chlorthalidone, Hydrochlorothiazide) reduce urinary calcium excretion—combining thiazides with high-dose Vitamin D + Calcium can precipitate hypercalcaemia! Digoxin: Hypercalcaemia from Vitamin D overdose triggers fatal digoxin cardiac arrhythmias! Phenytoin, Carbamazepine, Phenobarbitone, and Rifampicin induce CYP24A1 catabolism of Vitamin D (increasing requirements)
- Orlistat, Cholestyramine, and Liquid Paraffin block fat-soluble Vitamin D absorption
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: See Section 10.12 for the complete Vitamin D3 60,000 IU clinical protocol. Always write the exact 8-week stop/transition date on the pouch so the patient does not keep taking 60,000 IU every week for a year!
- Meal & Clock Timing Instruction: MUST be taken WITH a fat-containing meal or a glass of warm full-cream milk! (Vitamin D3 is highly lipophilic/fat-soluble; taking a 60,000 IU capsule or sachet with a meal containing healthy fats [milk, curd, ghee, nuts, dal] increases intestinal lymphatic absorption by 32% to 50% compared to taking it with plain water on an empty stomach!). (Once weekly (on a fixed day, e.g., Sunday) immediately after breakfast, lunch, or dinner (or with bedtime milk).)
- Missed Dose Protocol: If the weekly Sunday dose is forgotten, take it with a meal/milk on Monday or Tuesday, then resume the normal Sunday schedule the following week.
- Geriatric Dispensing Pearl: Correcting Vitamin D deficiency (<20 ng/mL) in elderly CGHS patients improves quadriceps muscle strength, reduces postural sway, reduces fall risk by ~20%, and prevents bisphosphonate-induced hypocalcaemia.
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: High-Strength Weekly/Monthly Oral Softgel Capsules, Chewable Tablets, Granule Sachets (1 g), & Oral Nano-Solution Shots (5 mL): 60,000 IU (1.5 mg Cholecalciferol); Daily Tablets: 1000 IU, 2000 IU; Parenteral IM Depot Injection (Arachitol): 3,00,000 IU, 6,00,000 IU (Use oral over mega-IM doses whenever possible!)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.2] (p. 127)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [10.10]-C117 Magnesium Bisglycinate — Essential Intracellular Divalent Cation (Cofactor for >300 ATP-De
- [10.12]-C118 Benfotiamine (Vitamin B1) — Essential Pyrophosphate Coenzyme for Carbohydrate Decarboxylation
- [10.16]-C122 Vitamin E (Tocopheryl Acetate) — Fat-Soluble Retinoid Epithelial/Visual Vitamin & Lipid-Peroxidati
- [10.16]-CMP123 Oral Isotretinoin (13-cis-Retinoic Acid) IP — Fat-Soluble Retinoid Epithelial/Visual Vitamin & Lipid-Peroxidati